Drug therapy for hypertension

American Family Physician

Volumn 55, Issue 5, 1997, Pages

  Gavras, Irene ^a   Manolis, Athanasios ^b   Gavras, Haralambos ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS CHLORTALIDONE; BETAXOLOL; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; INDAPAMIDE; LABETALOL; METHYLDOPA; METOLAZONE; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; PINDOLOL; PROPRANOLOL; SPIRONOLACTONE; TIMOLOL; TIMOLOL MALEATE; TORASEMIDE; TRIAMTERENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; BRONCHOSPASM; CARDIOTOXICITY; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; MENSTRUATION DISORDER; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; REVIEW; SOMNOLENCE; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION;

EID: 1842408332     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Herbert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153:578-81.
2. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64.
3. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991;338:1281-5.
4. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-7.
5. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-73.
6. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Progr Cardiovasc Dis 1986;29(3 Suppl 1):99-118.
7. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
8. Tobian L, Brunner HR, Cohn JN, Gavras H, Laragh JH, Materson BJ, et al. Modern strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V Consensus Guidelines. Am J Hypertens 1994;7(10 Pt 1):859-72.
9. Muller FB, Bolli P, Linder L, Kiowski W, Erne P, Buhler FR. Calcium antagonists and the second drug for hypertensive therapy. Am J Med 1986; 81(6A):25-9.
10. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
11. Packer M, Meller J, Medina N, Yushak M, Smith H, Holt J, et al Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation 1982;65:660-8.
12. Grimm RH Jr. Alpha 1-antagonists in the treatment of hypertension. Hypertension 1989;13(5 Suppl):131-6.
13. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA 1996;275:1577-80.
14. Maheux P, Facchini F, Jeppesen J, et al. Changes in glucose, insulin, lipid, lipoprotein and apoprotein concentrations and insulin-action in doxazosin-treated patients with hypertension: comparison between non-diabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens 1994;7:416-24.
15. Onesti G, Schwartz AB, Kim KE, Swartz C, Brest AN. Pharmacodynamic effects of a new antihypertensive drug, Catapres (ST-155). Circulation 1969;39:219-28.
16. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
17. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int 1992;42:1020-9.
18. Gavras H. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther 1986;9(Suppl 1):24-38.
19. Gavras H, Gavras I. Cardioprotective potential of angiotensin converting enzyme inhibitors [Editorial]. J Hypertens 1991;9:385-92.
20. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62 [Published erratum appears in N Engl J Med 1993;330:152].
22. Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clin Ther 1987;9:678-89.
23. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis 1974;17:87-98.
24. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA 1977;238:880-2.
25. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
26. Wang YX, Gavras I, Wierzba T, Gavras H. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin-converting enzyme inhibitor in conscious renovascular hypertensive rats. J Lab Clin Med 1992;119:267-72.
27. MacFadyen RJ, Reid JL. Angiotensin receptor antagonists as a treatment for hypertension [Editorial]. J Hypertens 1994;12:1333-8.
28. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, Lejemtel T, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88(4 Pt 1):1602-9.
29. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin n receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.